Teriflunomide: A Once-daily Oral Medication for the Treatment of Relapsing Forms of Multiple Sclerosis

Teriflunomide was approved by the US FDA in 2012 for treating relapsing forms of multiple sclerosis (RMS) based on Phase II and III trials, including TEMSO, TOWER, and TOPIC. The 14 mg dose significantly reduced the annualized relapse rate and risk of disability progression, while the 7 mg dose also reduced relapse rates but not disability progression. MRI measures showed reduced lesion activity with both doses. Safety data indicated common adverse events like headache, alopecia, and nausea. Teriflunomide was considered an effective treatment option for RMS, with specific precautions for women of childbearing potential.